27
Participants
Start Date
November 30, 2011
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2012
CK-2017357
Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
Placebo
Matching placebo tablets BID for 21 days
Riluzole 50 MG
Cornell Faculty, Hospital for Special Surgery, New York
Duke University School of Medicine, Division of Neurology, Durham
Ohio State University, Department of Neurology, Columbus
Washington University, St Louis
University of Texas Health Science Center, Department of Neurology, San Antonio
Coordinated Clinical Research, La Jolla
University of California at Irvine, ALS and Neuromuscular Center, Orange
University of California at San Francisco, Fresno Campus, Central California Neurological Institute, Fresno
Providence ALS Center, Portland
Hospital for Special Care, New Britain
Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown
Lead Sponsor
Cytokinetics
INDUSTRY